Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study.
Multi-centre trial
Myeloma
Quality control
Whole-body MRI
Journal
Insights into imaging
ISSN: 1869-4101
Titre abrégé: Insights Imaging
Pays: Germany
ID NLM: 101532453
Informations de publication
Date de publication:
15 Oct 2023
15 Oct 2023
Historique:
received:
11
05
2023
accepted:
08
08
2023
medline:
16
10
2023
pubmed:
16
10
2023
entrez:
15
10
2023
Statut:
epublish
Résumé
The Myeloma Response Assessment and Diagnosis System (MY-RADS) guidelines establish a standardised acquisition and analysis pipeline for whole-body MRI (WB-MRI) in patients with myeloma. This is the first study to assess image quality in a multi-centre prospective trial using MY-RADS. The cohort consisted of 121 examinations acquired across ten sites with a range of prior WB-MRI experience, three scanner manufacturers and two field strengths. Image quality was evaluated qualitatively by a radiologist and quantitatively using a semi-automated pipeline to quantify common artefacts and image quality issues. The intra- and inter-rater repeatability of qualitative and quantitative scoring was also assessed. Qualitative radiological scoring found that the image quality was generally good, with 94% of examinations rated as good or excellent and only one examination rated as non-diagnostic. There was a significant correlation between radiological and quantitative scoring for most measures, and intra- and inter-rater repeatability were generally good. When the quality of an overall examination was low, this was often due to low quality diffusion-weighted imaging (DWI), where signal to noise ratio (SNR), anterior thoracic signal loss and brain geometric distortion were found as significant predictors of examination quality. It is possible to successfully deliver a multi-centre WB-MRI study using the MY-RADS protocol involving scanners with a range of manufacturers, models and field strengths. Quantitative measures of image quality were developed and shown to be significantly correlated with radiological assessment. The SNR of DW images was identified as a significant factor affecting overall examination quality. ClinicalTrials.gov, NCT03188172 , Registered on 15 June 2017. Good overall image quality, assessed both qualitatively and quantitatively, can be achieved in a multi-centre whole-body MRI study using the MY-RADS guidelines. • A prospective multi-centre WB-MRI study using MY-RADS can be successfully delivered. • Quantitative image quality metrics were developed and correlated with radiological assessment. • SNR in DWI was identified as a significant predictor of quality, allowing for rapid quality adjustment.
Sections du résumé
BACKGROUND
BACKGROUND
The Myeloma Response Assessment and Diagnosis System (MY-RADS) guidelines establish a standardised acquisition and analysis pipeline for whole-body MRI (WB-MRI) in patients with myeloma. This is the first study to assess image quality in a multi-centre prospective trial using MY-RADS.
METHODS
METHODS
The cohort consisted of 121 examinations acquired across ten sites with a range of prior WB-MRI experience, three scanner manufacturers and two field strengths. Image quality was evaluated qualitatively by a radiologist and quantitatively using a semi-automated pipeline to quantify common artefacts and image quality issues. The intra- and inter-rater repeatability of qualitative and quantitative scoring was also assessed.
RESULTS
RESULTS
Qualitative radiological scoring found that the image quality was generally good, with 94% of examinations rated as good or excellent and only one examination rated as non-diagnostic. There was a significant correlation between radiological and quantitative scoring for most measures, and intra- and inter-rater repeatability were generally good. When the quality of an overall examination was low, this was often due to low quality diffusion-weighted imaging (DWI), where signal to noise ratio (SNR), anterior thoracic signal loss and brain geometric distortion were found as significant predictors of examination quality.
CONCLUSIONS
CONCLUSIONS
It is possible to successfully deliver a multi-centre WB-MRI study using the MY-RADS protocol involving scanners with a range of manufacturers, models and field strengths. Quantitative measures of image quality were developed and shown to be significantly correlated with radiological assessment. The SNR of DW images was identified as a significant factor affecting overall examination quality.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov, NCT03188172 , Registered on 15 June 2017.
CRITICAL RELEVANCE STATEMENT
UNASSIGNED
Good overall image quality, assessed both qualitatively and quantitatively, can be achieved in a multi-centre whole-body MRI study using the MY-RADS guidelines.
KEY POINTS
CONCLUSIONS
• A prospective multi-centre WB-MRI study using MY-RADS can be successfully delivered. • Quantitative image quality metrics were developed and correlated with radiological assessment. • SNR in DWI was identified as a significant predictor of quality, allowing for rapid quality adjustment.
Identifiants
pubmed: 37840055
doi: 10.1186/s13244-023-01498-3
pii: 10.1186/s13244-023-01498-3
pmc: PMC10577121
doi:
Banques de données
ClinicalTrials.gov
['NCT03188172']
Types de publication
Journal Article
Langues
eng
Pagination
170Subventions
Organisme : Cancer Research UK
ID : 25351
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 25354
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 25447
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 28677 (NCITA)
Pays : United Kingdom
Informations de copyright
© 2023. European Society of Radiology (ESR).
Références
Lancet Oncol. 2019 Jun;20(6):e302-e312
pubmed: 31162104
Eur J Radiol. 2019 Nov;120:108695
pubmed: 31589995
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Magn Reson Imaging. 2018 Nov;53:134-147
pubmed: 30036653
AJR Am J Roentgenol. 2012 Aug;199(2):252-62
pubmed: 22826385
Br J Haematol. 2017 Jan;176(2):222-233
pubmed: 27766627
Radiol Imaging Cancer. 2021 Sep;3(5):e210048
pubmed: 34559006
Leukemia. 2018 Jan;32(1):102-110
pubmed: 28584253
Eur Radiol. 2021 Jul;31(7):4514-4527
pubmed: 33409773
BMJ Open. 2021 Mar 24;11(3):e046225
pubmed: 33762245
J Magn Reson Imaging. 2015 Dec;42(6):1646-55
pubmed: 25952024
Br J Radiol. 2018 Jan;91(1081):20170577
pubmed: 29076749
Invest Radiol. 2016 Apr;51(4):255-65
pubmed: 26646309
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):529-537
pubmed: 31080095
Nat Rev Clin Oncol. 2017 Mar;14(3):169-186
pubmed: 27725679
J Magn Reson Imaging. 2014 Jul;40(1):26-36
pubmed: 24307538
Leukemia. 2009 Jan;23(1):3-9
pubmed: 18971951
Acad Radiol. 2018 Jul;25(7):904-914
pubmed: 29373210
Insights Imaging. 2022 Jul 28;13(1):123
pubmed: 35900614
Invest Radiol. 2022 Apr 1;57(4):272-281
pubmed: 34839306
Lancet Respir Med. 2019 Jun;7(6):523-532
pubmed: 31080129
Radiology. 2019 Apr;291(1):5-13
pubmed: 30806604